The DOI matches its Crossref record.
Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia
Abstract
Background: Heparin‐induced thrombocytopenia (HIT) is usually caused by anti‐platelet factor 4 (PF4)/heparin antibodies, leading to intravascular platelet activation. These antibodies can be detected by PF4/polyanion antigen assays or platelet activation assays. While antigen assays are very sensitive and recognize immunoglobulin (Ig)G, IgA, and IgM antibodies, the role of IgM and IgA HIT‐antibodies is debated. Platelet activation assays recognize IgG and are more specific for clinical HIT. Methods: We analyzed sera from 755 consecutive patients referred for diagnostic testing for HIT using a PF4/heparin enzyme‐linked immunosorbent assay (ELISA) for IgG, IgA, and IgM and by the heparin‐induced platelet activation (HIPA) test. Clinical information was provided by the treating physicians. Results: A total of 108 of 755 (14.3%) patients tested positive, 105 (13.9%) in the PF4/heparin IgG/A/M ELISA [28 (26.7%) only for IgM/A]; 53 (7.0%) sera were positive in the HIPA, of those 50 tested also positive in the ELISA. In 77 patients sufficient clinical information was provided. Available clinical information for 17 of the 28 patients who had only IgM and/or IgA detected showed plausible alternative (non‐HIT) explanations in four of seven who had thromboembolic complications and in nine of 10 who had isolated HIT. Conclusion: Detection of IgG, IgM and IgA class antibodies by PF4/heparin ELISA yields a positive test result about twice as often as does a platelet activation assay, with only a minority of the additional patients detected likely having HIT. Thus, there is a potential for considerable over‐diagnosis of HIT by laboratories that utilize only an ELISA for diagnostic testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Self-citationPathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., & Lester, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105385 · Cited by 964
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008) · Chest · doi:10.1378/chest.08-0677 · Cited by 816
Self-citationCuker, A., Gimotty, P. A., Crowther, M. A., & Warkentin, T. E. (2012) · Blood · doi:10.1182/blood-2012-07-443051 · Cited by 479
Metadata
- Authors
- Juhl, D., Eichler, P., Lubenow, N., Strobel, U., Wessel, A., & Greinacher, A.
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 2006-02-06
- Volume
- 76
- Issue
- 5
- Pages
- 420-426
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W2051545806
- Cited by
- 170
- References
- 0
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia. https://app.cochat.ai/papers/10.1111/j.1600-0609.2005.00621.x
- The paper
- Juhl, D., Eichler, P., Lubenow, N., Strobel, U., Wessel, A., & Greinacher, A. (2006). Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2005.00621.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.